Drug Combination Details
General Information of the Combination (ID: C65878) | |||||
---|---|---|---|---|---|
Name | Vincristine NP Info | + | Volasertib Drug Info | ||
Structure | + | ||||
Disease |
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Phase 1 | [1] | ||
Rhabdomyosarcoma
[ICD-11: 2B55]
|
Investigative | [2] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Enhancing Drug Efficacy by This Combination | ||||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [2] | |||||
In-vitro Model | A-204 | CVCL_1058 | Embryonal rhabdomyosarcoma | Homo sapiens | ||
RD | CVCL_1649 | Embryonal rhabdomyosarcoma | Homo sapiens | |||
Rh18 | CVCL_1659 | Alveolar rhabdomyosarcoma | Homo sapiens | |||
Rh30 | CVCL_0041 | Alveolar rhabdomyosarcoma | Homo sapiens | |||
Rh41 | CVCL_2176 | Alveolar rhabdomyosarcoma | Homo sapiens | |||
RMS-1 | CVCL_UF94 | Embryonal rhabdomyosarcoma | Homo sapiens | |||
RMS-YM | CVCL_A792 | Embryonal rhabdomyosarcoma | Homo sapiens | |||
Experimental
Result(s) |
Volasertib exhibits antitumor activity and synergy with vincristine in alveolar rhabdomyosarcoma. |